Tirzepatide vs Retatrutide
Medically reviewed by the Rite Aid Health Team · Last updated July 2, 2026
This comparison is mostly about today versus what may come next. Tirzepatide is an approved prescription medicine; retatrutide is still investigational, with promising trial data but no approved patient access outside studies.
Talk to a clinician about your options
GLP-1 medicines are prescription treatments. A licensed provider can review your history and help you choose and manage the right option — see peptides for weight loss for the broader picture.
At a glance
| Tirzepatide | Retatrutide | |
|---|---|---|
| Mechanism | Dual GLP-1 + GIP | Triple GLP-1 + GIP + glucagon |
| FDA status | Approved | Investigational (phase 3) |
| Availability | By prescription | Not available or approved |
| Cadence | Weekly injection | Weekly (in trials) |
| Key trial program | SURPASS-2 / SURMOUNT-1 | TRIUMPH-1 |
Trial program names are the labels drugmakers and researchers use for groups of related clinical studies. These links point to representative ClinicalTrials.gov records, not every study in each program.
How each works
Tirzepatide targets two incretin receptors; retatrutide adds a third (glucagon), which early trials suggest may drive greater weight loss. That evidence is still being gathered.
Where retatrutide stands
Retatrutide is investigational — it is not approved and cannot be prescribed. Any claims about it are based on unfinished trials.
The practical choice today
Only tirzepatide is an available, approved option, and it should be managed by a clinician.
Related
Educational information only. Any GLP-1 treatment should be started and supervised by a licensed clinician.
For general education only — not medical advice or a treatment recommendation. Peptides are not a substitute for care from a licensed provider. Talk to a qualified healthcare professional before you start, stop, or change any peptide, medication, or supplement.
FAQ
No. It is investigational and not approved for use outside clinical trials.
Early trial data has been striking, but it is unfinished and unapproved. It is too soon to call it better in any settled sense.